--- title: HUGM 2020 Registration Page --- [![BioIVT_4C_Logo w Tagline-01-1](https://info.bioivt.com/hs-fs/hubfs/BioIVT_4C_Logo%20w%20Tagline-01-1.png?width=250&name=BioIVT_4C_Logo%20w%20Tagline-01-1.png)](https://bioivt.com/)   LIVE VIRTUAL EVENT # HEPATOPAC® User Group Meeting OCTOBER 22, 2020 10 AM - 2:30 PM EST [Register Now](https://info.bioivt.com/hugm-reg-lp#register-form) ## Event Overview Our annual HEPATOPAC® User Group Meeting has gone virtual! This event will showcase the latest applications for HEPATOPAC cultures. Researchers from industry and academia will present how they have used HEPATOPAC cultures to investigate the ADME-Tox profiles of drug candidates and assess efficacy of new drugs in their lead selection programs. Join us for these presentations and discussions on how HEPATOPAC Technology is being used to advance drug discovery and development programs to: • Learn about our newest product, HEPATOMUNE® Cultures, for inflammation studies • Discover how your peers are using HEPATOPAC Technology • Understand how High-Content Imaging (HCI) is used to evaluate hepatic response • Explore how the technology is applied in liver disease (NAFLD) and infectious disease (HBV)research • Uncover opportunities for collaboration and ideas that you can use in your research **Can We Buy You Lunch?** Since our event has transitioned to a virtual event, we would like to offer any registrants a $20, €20, UberEats voucher.  When you fill out the registration form below select  whether you'd like to receive our lunch voucher. The voucher will be sent 24 hours before the start of the event.    ## Speakers ![Kang_HS](https://info.bioivt.com/hs-fs/hubfs/Kang_HS.jpg?width=392&height=390&name=Kang_HS.jpg) Wen Kang, PhD Senior Principal Scientist, Merck Dr. Kang is part of the Molecular and Investigative Toxicology group within Safety Assessment & Laboratory Animal Resources at Merck & Co. Her current work focuses on the development of *in vitro* cellular models and problem-solving tools to de-risk drug-induced liver toxicity in early drug development.  ![Chan_HS](https://info.bioivt.com/hs-fs/hubfs/Chan_HS.jpg?width=251&height=251&name=Chan_HS.jpg) Tom Chan, PhD Senior Principal Scientist, Boehringer Ingelheim Pharmaceuticals Dr. Chan joined the Drug Metabolism group at Boehringer Ingelheim Pharmaceuticals (BI) in 2009 as a Senior Scientist specializing in hepatocyte applications, and he spent his first few years investigating HEPATOPAC, a promising new technology from MIT. At BI. He currently leads a group of scientists with a focused interest on improving clinical drug-drug interaction predictions using novel *in vitro* technologies. ![Khetani_HS](https://info.bioivt.com/hs-fs/hubfs/Khetani_HS.jpg?width=392&height=390&name=Khetani_HS.jpg) Salman Khetani, PhD Associate Professor, University of Illinois at Chicago Dr. Khetani received his dual BS degrees in electrical engineering and biomedical engineering from Marquette University, and MS and PhD degrees in bioengineering from University of California at San Diego (UCSD).  Dr. Khetani’s 48+ publications in journals such as Hepatology, Nature Biotechnology, and PNAS have been cited more than 3500 times with an h-index of 25. Lastly, Dr. Khetani’s research has been funded over the last 10 years via ~$4.5 Min grants from the NIH, NSF, DOD, FDA, and the NSF CAREER award. ![Sarkis_HS_2](https://info.bioivt.com/hs-fs/hubfs/Sarkis_HS_2.png?width=371&height=372&name=Sarkis_HS_2.png) Joe Sarkis, PhD Principal Scientist, Moderna Therapeutics Originally from France, Dr. Sarkis obtained his Ph.D. at the Institute of Genetics & Development of Rennes-CNRS. He joined Moderna in 2017 and became a member of the Biological Science department, leading a group to better understand Lipid Nanoparticle (LNP) mechanism of uptake and identify models that help us identifying lead formulations for animal studies. List of papers can be found [here](https://scholar.google.nl/citations?user=Y_vqLlAAAAAJ&hl=en). ![Heyward_HS](https://info.bioivt.com/hs-fs/hubfs/Heyward_HS_WH.png?width=391&height=390&name=Heyward_HS_WH.png) Scott Heyward, MS Director, R&D, Scientific Affairs, BioIVT Prior to joining BioIVT, Scott worked in a number of academic institutions in a diverse set of biological areas spanning developmental biology, gene therapy, and virology, with a focus on hepatotropic viruses. As the Director of Research and Development for hepatic products in the ADME-Tox division for BioIVT, he focuses on both new product development as well as support of application development for our existing products.  ### Did you miss the 2019 meeting? Download the presentations from last year's event.  [Download the presentations.](https://info.bioivt.com/hugm-2019-materials) ## Agenda [Click here](https://info.bioivt.com/hubfs/Docs/BioIVT_HUGM%20Agenda_9232020.pdf) to view a PDF for more information about the speakers and the presentation abstracts.  10:00 - 10:05 Opening Remarks Speaker: Chris Black, PhD, Senior Vice President, ADME-Tox, BioIVT 10:05 - 11:00 HEPATOPAC: Past, Present, and Future Applications in Drug Development Speaker: Dr. Salman Khetani, Associate Professor, University of Illinois at Chicago 11:00 - 12:00 Development and Application of a Transcriptomic Signature of Bioactivation in the HEPATOPAC Model to Reduce Drug-induced Liver Injury Risk Early in Small Molecule Drug Development Speaker: Wen Kang, PhD, Senior Principal Scientist, Merck 12:00 - 01:00 HEPATOPAC use at Boehringer Ingelheim Pharmaceuticals: A Decade of Learning Speaker: Tom Chan, PhD, Senior Principal Scientist, Boehringer Ingelheim Pharmaceuticals 01:00 - 01:40 Live Imaging of HEPATOPAC to Characterize LNP Delivery to Hepatocytes and mRNA Expression in Hepatocytes Speaker: Joe Sarkis, PhD, Principal Scientist, Moderna Therapeutics 01:40 - 02:20 Incorporation of Kupffer Cells in Long Term Hepatocyte Cultures in the HEPATOMUNE® Model Speaker: Scott Heyward, MS, Director, R&D, Scientific Affairs, BioIVT 02:20 - 02:30 Closing Remarks Speaker: Scott Heyward, MS, Director, R&D, Scientific Affairs, BioIVT ## Save Your Seat ### Sign up for our newsletter We’ll send you periodic updates about new products and services BioIVT will use the information you have provided above to service your request/inquiry. In addition, our sales and marketing team would like to use your contact information to connect with you about specific BioIVT products and services that we think might be of interest to you. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our [Privacy Policy](https://www.bioivt.com/privacy-policy/). ### Questions? You can reach us by phone, email or [click here to contact us.](https://www.bioivt.com/about/contact-us/) ### North America & Asia Pacific [516-483-1196](tel:516-483-1196) [customerservice@bioivt.com](mailto:customerservice@bioivt.com) ### Europe, Middle East & Africa [+ 44 1444 707333](tel:+%2044%201444%20707333) [cseurope@bioivt.com](mailto:cseurope@bioivt.com) ©2020 BioIVT. BIOIVT and ELEVATING SCIENCE are a registered trademarks of BioIVT. - [Trademarks](https://www.bioivt.com/trademarks) - [Privacy Policy](https://www.bioivt.com/privacy-policy) - [Terms and Conditions](https://www.bioivt.com/terms-and-conditions)